# Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

> **NCT03773133** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 9 (actual)

## Conditions studied

- Small Cell Lung Cancer and Breast Cancer

## Interventions

- **DRUG:** Satoreotide tetraxetan
- **DRUG:** Satoreotide trizoxetan

## Key facts

- **NCT ID:** NCT03773133
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-14
- **Primary completion:** 2019-10-10
- **Final completion:** 2019-10-10
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** High number of screen failures
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03773133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03773133, "Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03773133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*